Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia Find H1N1 Strain Resistant To Locally Discovered Relenza

This article was originally published in PharmAsia News

Executive Summary

Australian researchers report the H1N1 flu virus has mutated into a form that could be resistant to the second of the two main antivirals available to treat the disease. They said a strain has been found in laboratory tests, but not yet so far in a patient, that is resistant to Australian-developed Relenza (zanamivir), produced by U.K.-based GlaxoSmithKline. A spokeswoman for Australia's Biota, which discovered the drug, said there is no evidence the mutation has infected patients, so the clinical significance of the report cannot be determined yet. Roche's Tamiflu (oseltamivir) already has been discovered to have an H1N1 strain that is resistant to it. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel